Refractory Metastatic Melanoma - Pipeline Insight, 2021

Refractory Metastatic Melanoma - Pipeline Insight, 2021

  • February 2021 •
  • 60 pages •
  • Report ID: 6022106 •
  • Format: PDF
“Refractory Metastatic Melanoma - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Refractory metastatic melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Refractory Metastatic Melanoma Understanding

Refractory Metastatic Melanoma: Overview
Refractory metastatic melanoma is the neoplasm of the melanocytes (melanin producing cells). Though melanoma is not common but are the most serious type of skin cancer. Melanoma can develop anywhere on the skin, it can also occur in eyes and other parts of body and on very rare occasions in intestine. Metastatic melanoma can invade the lymphatic system and spread. Exact cause of melanoma is still unclear, however the mutation in DNA of melanocyte due to exposure to UV rays, and other environmental factors are likely to be the leading cause for melanomas. Melanomas can affect both sexes equally. Individuals with history of sunburn, weakened immune system, many moles or unusual moles on the body, excessive exposure to the ultraviolet radiations, and family-history of melanoma are more prone to develop metastatic melanoma.

“Refractory Metastatic Melanoma - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Refractory Metastatic Melanoma pipeline landscape is provided which includes the disease overview and Refractory Metastatic Melanoma treatment guidelines. The assessment part of the report embraces, in depth Refractory Metastatic Melanoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Metastatic Melanoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Refractory metastatic melanoma R&D. The therapies under development are focused on novel approaches to treat/improve Refractory metastatic melanoma.

Refractory Metastatic Melanoma Emerging Drugs Chapters
This segment of the Refractory metastatic melanoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Refractory metastatic melanoma Emerging Drugs
• IMO-2125: Idera Pharmaceuticals
Idera Pharmaceuticals’ new drug candidate, IMO-2125, is an intratumoral injection in development for the treatment of refractory metastatic melanoma from staged II b to IV. The drug has demonstrated good efficacy in its phase I and phase II clinical trials. IMO-2125 is a toll-like receptor agonist that signals the immune system to create and activate cancer-fighting cells (T-cells) to target solid tumors in refractory melanoma patients.

• Linrodostat: Bristol-Myers Squibb
Bristol’s “breakthrough” drug Linrodostat is an orally administered drug molecule is currently being evaluated for the treatment of refractory metastatic melanoma and has demonstrated good safety and tolerability in Phase I trials. Linrodostat is an inhibitor of indoleamine 2, 3-deoxygenase 1 (IDO1) with potential immunomodulating and antineoplastic activities.
Further product details are provided in the report……..

Refractory Metastatic Melanoma: Therapeutic Assessment
This segment of the report provides insights about the different Refractory metastatic melanoma drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Refractory Metastatic Melanoma
There are approx. 10+ key companies which are developing the therapies for Refractory metastatic melanoma. The companies which have their Refractory metastatic melanoma drug candidates in the mid to advanced stage, i.e. phase III include, Idera Pharmaceuticals and others.

Phases
report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Refractory metastatic melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as
• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Refractory Metastatic Melanoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Refractory metastatic melanoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Refractory metastatic melanoma drugs.

Refractory Metastatic Melanoma Report Insights
• Refractory metastatic melanoma Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Refractory Metastatic Melanoma Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Refractory metastatic melanoma drugs?
• How many Refractory metastatic melanoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Refractory metastatic melanoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Refractory metastatic melanoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Refractory metastatic melanoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Idera Pharmaceuticals
• Bristol-Myers Squibb
• Sunesin Pharmaceuticals
• Taiga biotechnologies
• BioNtech

Key Products
• IMO-2125
• Linrodostat
• MLN 2480
• TBX 3400
• BNT 111